CryoCath Introduces Arctic Front in Australia

    Toronto Stock Exchange Symbol: CYT

    MONTREAL, March 26 /CNW/ - CryoCath(R) Technologies Inc., the global
leader in cryotherapy products to treat cardiac arrhythmias, today announced
the introduction of Arctic Front(R) in Australia. Arctic Front, the company's
lead product for the treatment of paroxysmal atrial fibrillation (PAF), is a
unique cryoablation balloon catheter that allows physicians to safely and
effectively isolate all four pulmonary veins to stop PAF.
    On March 13 and 14, a group of nine Australian electrophysiologists
attended the training program for the Arctic Front system in Melbourne,
Australia. Leadership of this program was in the hands of Dr. Jeff Alison,
Head of Electrophysiology and Pacing of the Monash Medical Centre in
Melbourne, Australia, and Dr. Yves Van Belle of the Thorax Centrum at the
Erasmus University in Rotterdam, The Netherlands. Dr. Van Belle is one of the
most experienced users of the Arctic Front system and the author of the first
publication on this groundbreaking device in a peer reviewed journal.
Dr. Alison has received training on the system both in Germany as well as in
Montreal. He has also performed the first Arctic Front procedure in Australia
in late 2007.
    "Arctic Front holds the promise of a breakthrough therapy in the
treatment of paroxysmal atrial fibrillation. The data out of Europe strongly
supports this belief and we're excited to be able to offer a potentially safer
and effective treatment to our patients," said Dr. Alison. "Thousands of
Australians suffer from the symptoms of PAF, and a safe and effective therapy
can bring a substantial benefit to these patients."
    Solid professional education is the foundation of a successful
introduction of a new technology. In the first Arctic Front Masters Program
(AFMP) held in Australia, nine physicians from two centers were trained on the
new technology. As part of the curriculum, they observed two successful
procedures performed by Dr. Alison. Through the efforts of Life Systems
Medical Inc., CryoCath's exclusive distributor in Australia, an extensive
follow-up training program was completed. As a result of this successful
program, several first Arctic Front procedures were performed in two further
hospitals across Australia over the past few days.
    "We're happy to see the rapid growth in the use of Arctic Front now
expanding beyond Europe. The rapidly increasing body of positive clinical
evidence for the Arctic Front system gives us great confidence that we can
continue to show a fast expansion of our user base," said Jan Keltjens,
President and CEO of CryoCath. "I am impressed with the efforts of Life
Systems Medical and the support from thought leaders in Australia. Well over
2,000 patients across 34 centres in Europe have been treated to date with
Arctic Front. The introduction in Australia will further accelerate this
momentum and bring the benefits of this breakthrough therapy to large groups
of patients."

    About CryoCath

    CryoCath - - is a medical technology company that leads
the world in cryotherapy products to treat cardiac arrhythmias. With a
priority focus on providing physicians with a complete solution of catheter
products to treat cardiac arrhythmias, CryoCath has multiple products approved
in the U.S., across Europe and several ROW countries. The Company is
developing additional products to expand its pipeline of products to treat
cardiac arrhythmias.

    This press release includes "forward-looking statements" that are subject
to risks and uncertainties, including with respect to the timing of regulatory
trials and their outcome. For information identifying legislative or
regulatory, economic, climatic, currency, technological, competitive and other
important factors that could cause actual results to differ materially from
those anticipated in the forward-looking statements, see CryoCath's annual
report available at under the heading Risks and Uncertainties in
the Management's Discussion and Analysis section.

    %SEDAR: 00015053EF

For further information:

For further information: visit our website at, or
contact: Michael Moore, Investor Relations, Phone: (416) 815-0700 ext. 241,
Fax: (416) 815-0080, E-mail:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890